论文部分内容阅读
目的:观察柔木丹颗粒联合恩替卡韦治疗乙型肝炎肝纤维化的疗效。方法:将90例乙型肝炎肝纤维化患者随机分为治疗组和对照组各45例,两组均予以恩替卡韦分散片治疗,治疗组加用柔木丹颗粒治疗,疗程均为24周。结果:两组治疗后综合疗效比较,差异有统计学意义(P=0.041),治疗组优于对照组;治疗组改善肝功能(ALT、r-GT、TBIL)情况优于对照组(P=0.021、P=0.015、P=0.012),并很好地降低血清肝纤维化指标(HA,P=0.022;LN,P=0.000)。结论:柔木丹颗粒联合恩替卡韦治疗乙型肝炎肝纤维化有较好疗效,可改善患者的肝功能,降低患者的肝纤维化指标。
Objective: To observe the efficacy of softwood granules combined with entecavir in treating hepatitis B liver fibrosis. Methods: 90 patients with hepatitis B liver fibrosis were randomly divided into treatment group and control group of 45 cases, both groups were treated with entecavir dispersible tablets, the treatment group with Roumudan particles were treated for 24 weeks. Results: The curative effect of the two groups after treatment was statistically significant (P = 0.041), and the treatment group was better than the control group. The improvement of liver function (ALT, r-GT and TBIL) in the treatment group was better than that in the control group (P = 0.021, P = 0.015, P = 0.012), and decreased serum hepatic fibrosis indicators (HA, P = 0.022; LN, P = 0.000). Conclusion: The combination of softwood granules and entecavir has good curative effect on hepatitis B liver fibrosis, which can improve the liver function and reduce the index of liver fibrosis in patients.